195 related articles for article (PubMed ID: 19040611)
21. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
22. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells.
Weisburg JH; Roepe PD; Dzekunov S; Scheinberg DA
J Biol Chem; 1999 Apr; 274(16):10877-88. PubMed ID: 10196165
[TBL] [Abstract][Full Text] [Related]
23. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
24. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
[TBL] [Abstract][Full Text] [Related]
25. Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.
Bjørge L; Junnikkala S; Kristoffersen EK; Hakulinen J; Matre R; Meri S
Br J Cancer; 1997; 75(9):1247-55. PubMed ID: 9155042
[TBL] [Abstract][Full Text] [Related]
26. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Yano S; Sone S; Nishioka Y; Naito M; Tsuruo T; Ogura T
Jpn J Cancer Res; 1994 Feb; 85(2):194-203. PubMed ID: 7511575
[TBL] [Abstract][Full Text] [Related]
28. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Oct; 82(4):544-7. PubMed ID: 9806185
[TBL] [Abstract][Full Text] [Related]
29. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
30. A novel bioassay for P-glycoprotein functionality using cytochalasin D.
Elbling L; Berger W; Weiss RM; Printz D; Fritsch G; Micksche M
Cytometry; 1998 Mar; 31(3):187-98. PubMed ID: 9515718
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
32. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
[TBL] [Abstract][Full Text] [Related]
33. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
35. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
36. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
38. Pyramidatine (Z88) Sensitizes Vincristine-Resistant Human Oral Cancer (KB/VCR) Cells to Chemotherapeutic Agents by Inhibition of P-glycoprotein.
Liu Z; Zhu H; Qu S; Tang L; Cao L; Yu W; Yang X; Jiang S; Zhu D; Tan C; Yu L
Anticancer Agents Med Chem; 2018; 18(2):286-294. PubMed ID: 28782465
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
40. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
Shrivastava P; Hanibuchi M; Yano S; Parajuli P; Tsuruo T; Sone S
Cancer Chemother Pharmacol; 1998; 42(6):483-90. PubMed ID: 9788575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
